TIGIT and non-small cell lung carcinoma: In addition, a dose-finding study in NSCLC patients found that anti-TIGIT monoclonal antibodies are generally well tolerated, with no grade 3–4 adverse events for monotherapy, and grade 3–4 irAEs occurring in only 10% of patients treated with anti-TIGIT combined with pembrolizumab [70,83].